Hans Clevers MD PhD, has been a Venture Partner with LSP since 2001, except during the period June 2012-May 2015, when he was President of the Royal Netherlands Academy of Arts and Sciences (KNAW). Hans has been an important member of the LSP team given his vast scientific network and exceptional scientific expertise, in particular in the field of oncology. Hans studied medicine and biology at Utrecht University and did his postdoc at Harvard. From 1991 to 2012, he was professor of immunology and molecular genetics at Utrecht University. From 2002 to 2012, he was director of the Hubrecht Institute, one of the seventeen KNAW institutes. He is also an honorary professor at Central South University in Changsha, Hunan, China. Hans has received many prestigious awards, including the Spinoza Prize (2001), the Louis-Jeantet Prize (2004), the Josephine Nefkens Prize for Cancer Research (2008), the Kolff Prize (2011), the Léopold Griffuel Prize (in 2011 and 2012), the Heineken Prize for Medicine (2012), and the 2013 Breakthrough Prize for Life Sciences, a $3 million highly prestigious international award. He has authored numerous publications in leading journals, including Nature, Science and Cell.
His research deals with the intestine. He has described the molecular signalling pathways that are disrupted by cancer and has been able to grow 'mini-intestines' from individual stem cells, the first step on the road to regenerative medicine. Hans holds a dozen patents and was involved in setting up a number of biotechnology companies. Hans founded U-BiSys in 1996, a LSP start-up investment which merged with IntroGene (another LSP investment) to become Crucell in 2000. Crucell was acquired in 2010 by the pharmaceutical company Johnson & Johnson for $ 2.6 billion. Hans was also involved in LSP’s companies Semaia and Hybrigenics.
Hans will be appointed Head of Roche Pharma Research and Early Development (pRED) and a member of the Roche’s Corporate Executive Committee as of 18 March 2022. As a consequence, his Venture Partner activities will be ended on 1 July 2022.